跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CXCR4 (Ligand)
首页
药物
CXCR4 (Ligand)
CXCR4 (Ligand)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF
US 20250288704 A1
申请人: UNIV MUENCHEN TECH
优先权: 2021
CN
EP
US
WO
5 件公开
Cancer imaging and treatment
US 8628750 B2
申请人: WESTER HANS JUERGEN
优先权: 2006
EP
US
WO
5 件公开
CN 101454340 A
申请人: UNIV MUENCHEN TECH
优先权: 2006
CN
Methods and compositions for ameliorating pancreatic cancer
US 9267934 B2
申请人: SINGH SEEMA
优先权: 2011
US
3 件公开
Small peptide compositions and uses thereof
US 11338017 B2
申请人: UNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
优先权: 2019
US
3 件公开
Chemical Compounds
US 2008045537 A1
申请人: GUDMUNDSSON KRISTJAN
优先权: 2004
CN
US
2 件公开
CN 101052399 A
申请人: SMITHKLINE BEECHAM CORP
优先权: 2004
CN
2 件公开
US 2007232615 A1
申请人: GUDMUNDSSON KRISTIAN
优先权: 2005
US
2 件公开
US 2008096861 A1
申请人: SMITHKLINE BEECHAM CORP
优先权: 2005
US
US 2008171740 A1
申请人: SMITHKLINE BEECHAM CORP
优先权: 2005
US
US 2008207634 A1
申请人: GUDMUNDSSON KRISTJAN
优先权: 2005
US
US 2008214562 A1
申请人: GUDMUNDSSON KRISTJAN
优先权: 2006
US
US 2008234318 A1
申请人: GUDMUNDSSON KRISTJAN
优先权: 2006
US
US 2010280010 A1
申请人: GUDMUNDSSON KRISTJAN
优先权: 2007
US
Compositions and methods for tissue engineering and cell based therapies
US 9682078 B2
申请人: BOTCHWEY III EDWARD A
优先权: 2012
US
2 件公开
Natural killer cell for transgenic expression cell chemotactic factors
CN 1629285 A
申请人: GONG XIAODI
优先权: 2003
CN
Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs53 upregulation
US 2005221287 A1
申请人: CONSEJO SUPERIOR INVESTIGACION
优先权: 2005
US
Methods to enhance chemotherapy
US 2007043012 A1
申请人: BRIDGER GARY J
优先权: 2006
US
TREATMENT OF CANCER BY COMBINED BLOCKADE OF THE PD-1 AND CXCR4 SIGNALING PATHWAYS
CN 108026173 A
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2015
CN
第 1 / 3 页
上一页
下一页
药物
反馈